Last checked at 10 Mar 2010 16:01
| Press Release | 10 March 2010 |
e-Therapeutics plc
("e-Therapeutics" or "the Company")
Director's interest
e-Therapeutics plc (AIM: ETX), the network drug discovery and development company, announces that on 9 March 2010, the expiration date of John Cordiner's option over 356,870 ordinary shares in the Company has been extended from the original expiry date of 10 March 2010 to 10 March 2013. All others conditions of this option are unchanged.
- Ends -
| For more information: |
|
| e-Therapeutics plc | www.etherapeutics.co.uk |
| Malcolm Young malcolm@etherapeutics.co.uk | +44 (0) 191 233 1317 |
| Nominated Advisor & Broker: Canaccord Adams Ltd | www.canaccordadams.com |
| Robert Finlay / Henry Fitzgerald-O'Connor henry.fitzgerald-o'connor@canaccordadams.com | +44 (0) 20 7050 6500 |
| Media enquiries: Abchurch Communications | www.abchurch-group.com |
| Heather Salmond / Simone Elviss / Hannah Sharman simone.elviss@abchurch-group.com | +44 (0) 20 7398 7700
|
Notes to Editors
About e-Therapeutics
e-Therapeutics plc pioneered network pharmacology in drug discovery. It has developed proprietary systems to swiftly and accurately analyse and predict how medicines interact with cells in the body. This optimises the probability of identifying drug candidates with desirable efficacy and low toxicity. The Company applies its novel, systematic approach to three areas of activity:
| ·; | discovery of new drugs; |
| ·; | discovering novel uses for existing drugs; and |
| ·; | analysis of the interactions between different drugs. |
Amongst e-Therapeutics' pipeline of compounds in development are novel antibiotics that have been shown to kill the "superbug" MRSA and C.difficile, and a novel cancer chemotherapy that has been shown to kill malignant cells at safe doses in a very short time. Other candidate therapies in development are targeted at atherosclerosis, asthma and depression. The Company is currently in negotiation with a number of pharmaceutical companies, and is progressing the preclinical and clinical development of these products, two of which have completed Phase II trials successfully, and three of which have been out-licensed to pharmaceutical partners.
For further information on e-Therapeutics visit www.etherapeutics.co.uk